基于crispr - cas的抗微生物药物耐药性策略的进展

IF 6.1 1区生物学 Q1 MICROBIOLOGY

Microbiological research Pub Date : 2025-05-22 DOI:10.1016/j.micres.2025.128232

Ruiting Zhang, Qi Zhou, Siying Huang, Nan Zhang, Dongchang Sun

{"title":"基于crispr - cas的抗微生物药物耐药性策略的进展","authors":"Ruiting Zhang, Qi Zhou, Siying Huang, Nan Zhang, Dongchang Sun","doi":"10.1016/j.micres.2025.128232","DOIUrl":null,"url":null,"abstract":"<div><div>Multidrug resistance (MDR) in bacteria presents a significant global health threat, driven by the widespread dissemination of antibiotic-resistant genes (ARGs). The CRISPR-Cas system, known for its precision and adaptability, holds promise as a tool to combat antimicrobial resistance (AMR). Although previous studies have explored the use of CRISPR-Cas to target bacterial genomes or plasmids harboring resistance genes, the application of CRISPR-Cas-based antimicrobial therapies is still in its early stages. Challenges such as low efficiency and difficulties in delivering CRISPR to bacterial cells remain. This review provides an overview of the CRISPR-Cas system, highlights recent advancements in CRISPR-Cas-based antimicrobials and delivery strategies for combating AMR. The review also discusses potential challenges for the future development of CRISPR-Cas-based antimicrobials. Addressing these challenges would enable CRISPR therapies to become a practical solution for treating AMR infections in the future.</div></div>","PeriodicalId":18564,"journal":{"name":"Microbiological research","volume":"298 ","pages":"Article 128232"},"PeriodicalIF":6.1000,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Advancements in CRISPR-Cas-based strategies for combating antimicrobial resistance\",\"authors\":\"Ruiting Zhang, Qi Zhou, Siying Huang, Nan Zhang, Dongchang Sun\",\"doi\":\"10.1016/j.micres.2025.128232\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Multidrug resistance (MDR) in bacteria presents a significant global health threat, driven by the widespread dissemination of antibiotic-resistant genes (ARGs). The CRISPR-Cas system, known for its precision and adaptability, holds promise as a tool to combat antimicrobial resistance (AMR). Although previous studies have explored the use of CRISPR-Cas to target bacterial genomes or plasmids harboring resistance genes, the application of CRISPR-Cas-based antimicrobial therapies is still in its early stages. Challenges such as low efficiency and difficulties in delivering CRISPR to bacterial cells remain. This review provides an overview of the CRISPR-Cas system, highlights recent advancements in CRISPR-Cas-based antimicrobials and delivery strategies for combating AMR. The review also discusses potential challenges for the future development of CRISPR-Cas-based antimicrobials. Addressing these challenges would enable CRISPR therapies to become a practical solution for treating AMR infections in the future.</div></div>\",\"PeriodicalId\":18564,\"journal\":{\"name\":\"Microbiological research\",\"volume\":\"298 \",\"pages\":\"Article 128232\"},\"PeriodicalIF\":6.1000,\"publicationDate\":\"2025-05-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Microbiological research\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0944501325001880\",\"RegionNum\":1,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Microbiological research","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0944501325001880","RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

由于抗生素耐药基因（ARGs）的广泛传播，细菌中的多药耐药（MDR）对全球健康构成了重大威胁。CRISPR-Cas系统以其精确性和适应性而闻名，有望成为对抗抗菌素耐药性（AMR）的工具。尽管之前的研究已经探索了利用CRISPR-Cas靶向细菌基因组或含有耐药基因的质粒，但基于CRISPR-Cas的抗菌疗法的应用仍处于早期阶段。将CRISPR传递到细菌细胞的低效率和困难等挑战仍然存在。本文综述了CRISPR-Cas系统，重点介绍了基于CRISPR-Cas的抗菌剂和抗AMR的递送策略的最新进展。这篇综述还讨论了基于crispr - cas的抗菌剂未来发展的潜在挑战。解决这些挑战将使CRISPR疗法在未来成为治疗AMR感染的实用解决方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Advancements in CRISPR-Cas-based strategies for combating antimicrobial resistance

Multidrug resistance (MDR) in bacteria presents a significant global health threat, driven by the widespread dissemination of antibiotic-resistant genes (ARGs). The CRISPR-Cas system, known for its precision and adaptability, holds promise as a tool to combat antimicrobial resistance (AMR). Although previous studies have explored the use of CRISPR-Cas to target bacterial genomes or plasmids harboring resistance genes, the application of CRISPR-Cas-based antimicrobial therapies is still in its early stages. Challenges such as low efficiency and difficulties in delivering CRISPR to bacterial cells remain. This review provides an overview of the CRISPR-Cas system, highlights recent advancements in CRISPR-Cas-based antimicrobials and delivery strategies for combating AMR. The review also discusses potential challenges for the future development of CRISPR-Cas-based antimicrobials. Addressing these challenges would enable CRISPR therapies to become a practical solution for treating AMR infections in the future.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Microbiological research 生物-微生物学

CiteScore

10.90

自引率

6.00%

发文量

249

审稿时长

29 days

期刊介绍： Microbiological Research is devoted to publishing reports on prokaryotic and eukaryotic microorganisms such as yeasts, fungi, bacteria, archaea, and protozoa. Research on interactions between pathogenic microorganisms and their environment or hosts are also covered.